Interestingly, despite regulating just 9/25 splicing events of the basal B-specific splicing signature, low expression of RBM47, and not ESRP1, correlated with a poor prognosis and lower survival rate in basal-like breast cancer patients, which increases the interest to design new therapies targeting this splicing regulator. Here, ESRP1 is linked to breast carcinoma.